Literature DB >> 19081234

Lung function changes following methacholine inhalation in COPD.

Paul P Walker1, Justine Hadcroft, Richard W Costello, Peter M A Calverley.   

Abstract

BACKGROUND: The non-specific bronchial hyper-responsiveness reported in mild to moderate COPD is usually attributed to reduced airway calibre accentuating the effect of airway smooth muscle shortening. We hypothesized that in more severe COPD the fall in forced expiratory volume in 1 second (FEV(1)) seen during methacholine challenge would result from an increase in residual volume and decrease in vital capacity rather than an increase in airways resistance.
METHODS: Twenty-five subjects with moderate to severe COPD and 10 asthmatic subjects had spirometry and oscillatory mechanics measured before methacholine challenge and at a 20% fall from baseline post challenge (PC(20)FEV(1)).
RESULTS: In the COPD subjects median PC(20) was 0.35mg/mL. Comparing baseline to PC(20) there were significant falls in forced vital capacity (FVC) (2.91 vs. 2.2L; p<0.001), slow vital capacity (3.22 vs. 2.58L; p<0.001) and IC (2.21 vs. 1.75L; p<0.001) without change in FEV(1)/FVC ratio (0.52 vs. 0.52; not significant) or in total lung capacity where this was measured. Total respiratory system resistance (R(5)) was unchanged (0.66 vs. 0.68; not significant) but total respiratory system reactance decreased significantly (-0.33 vs. -0.44; p<0.001). In contrast, the asthmatics became more obstructed and showed a proportionally smaller fall in lung volume with increase in R(5) (0.43 vs. 0.64; p<0.01).
CONCLUSIONS: In moderate to severe COPD the fall in FEV(1) with methacholine is mainly due to increases in residual volume, which may represent airway closure and new-onset expiratory flow limitation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19081234     DOI: 10.1016/j.rmed.2008.11.002

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  7 in total

Review 1.  Targeting patients with asthma for omalizumab therapy: choosing the right patient to get the best value for money.

Authors:  Abir Al Said; Breda Cushen; Richard W Costello
Journal:  Ther Adv Chronic Dis       Date:  2017-02-01       Impact factor: 5.091

2.  Clinical predictors of frequent exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD).

Authors:  Emily S Wan; Dawn L DeMeo; Craig P Hersh; Steven D Shapiro; Richard A Rosiello; Susan R Sama; Anne L Fuhlbrigge; Marilyn G Foreman; Edwin K Silverman
Journal:  Respir Med       Date:  2010-12-10       Impact factor: 3.415

3.  Sensitivity of Lung Resistance and Compliance to Beta-Blocker Induced Bronchoconstriction and Long Acting Beta-Agonist Withdrawal in COPD.

Authors:  Sunny Jabbal; Brian J Lipworth
Journal:  Lung       Date:  2017-12-20       Impact factor: 2.584

4.  I Say IOS You Say AOS: Comparative Bias in Respiratory Impedance Measurements.

Authors:  Chris RuiWen Kuo; Sunny Jabbal; Brian Lipworth
Journal:  Lung       Date:  2019-07-04       Impact factor: 2.584

5.  Integrated OMICs Approach for the Group 1 Protease Mite-Allergen of House Dust Mite Dermatophagoides microceras.

Authors:  Rei-Hsing Hu; Chun-Wen Cheng; Chia-Ta Wu; Jiunn-Liang Ko; Ko-Huang Lue; Yu-Fan Liu
Journal:  Int J Mol Sci       Date:  2022-03-30       Impact factor: 5.923

6.  Increased matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio in smokers with airway hyperresponsiveness and accelerated lung function decline.

Authors:  Chun-Yu Lo; Hung-Yu Huang; Jung-Ru He; Tzu-Ting Huang; Chih-Chen Heh; Te-Fang Sheng; Kian Fan Chung; Han-Pin Kuo; Chun-Hua Wang
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-04-11

Review 7.  ACO (Asthma-COPD Overlap) Is Independent from COPD: The Case in Favour.

Authors:  Peter M A Calverley; Paul Phillip Walker
Journal:  Diagnostics (Basel)       Date:  2021-06-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.